Caribou Biosciences

Rachel Haurwitz, Ph.D., President & CEO
Berkeley, CA
(Private)
Caribou is a pioneer in the revolutionary field of CRISPR genome editing. Caribou’s proprietary technology puts it at the forefront of the development of allogeneic cellular therapies. Caribou is developing an internal, wholly-owned pipeline of off-the-shelf CAR-T cell therapies and gene-edited natural killer (NK) cell therapies. The company’s focus is centered on oncology and the pipeline includes programs for both liquid and solid tumor targets. Caribou’s next-gen CRISPR gene editing technology drives higher specificity editing than first-generation CRISPR-Cas9. The company deploys gene editing to carry out multiple edits to boost T-cell persistence and to prevent GvHD. CB-010, the company’s lead program, is an allogeneic anti-CD19 CAR-T therapy where PD-1 has been removed from the CAR-T genome. The durability of anti-tumor activity achieved with CB-010 in vivo significantly surpasses the durability of CAR-Ts where PD-1 remains on.
www.cariboubio.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions